SCHEMBL12346328

SCHEMBL12346328

CNC(=O)Nc1ccc(-c2cncc3[nH]nc(N)c23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.72
KIT P10721 15/20 0.72
FLT3 P36888 15/20 0.72
LCK P06239 6/20 0.72
CSF1R P07333 6/20 0.72
FLT1 P17948 6/20 0.72
FLT4 P35916 6/20 0.72
LYN P07948 5/20 0.72
SRC P12931 5/20 0.72
BLK P51451 5/20 0.72
FYN P06241 4/20 0.72
ABL1 P00519 2/20 0.72
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
ROCK2 O75116 2/20 0.58
INSR P06213 2/20 0.58
MET P08581 2/20 0.58
FGFR1 P11362 2/20 0.58
PRKACA P17612 2/20 0.58
RPS6KB1 P23443 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16475318 0.84 KDR (0.80) KDRKITFLT3LCKCSF1R
SCHEMBL233874 0.84 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL1703142 0.83 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL1703478 0.82 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL1703302 0.81 KDR (0.79) KDRKITFLT3LCKCSF1R
SCHEMBL1702794 0.81 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL12346318 0.79 KDR (0.76) KDRKITFLT3LCKCSF1R
SCHEMBL1702799 0.77 KDR (1.00) KDRKITFLT3LCKCSF1R
SCHEMBL12426039 0.77 KDR (0.77) KDRKITFLT3LCKCSF1R
SCHEMBL2236827 0.76 KDR (0.78) KDRKITFLT3LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008322-B2 Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use AVENTIS PHARMA S.A. (FR) 2011-08-30 US disclosed
US-20110190337-A1 SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AVENTIS PHARMA S.A.. (FR) 2011-08-04 US disclosed
US-20080039491-A1 SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AVENTIS PHARMA S.A. (FR) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190337-A1 SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE DPYD, TYMP, PCK2 KDR 2947/4885KIT 358/4885FLT3 121/4885
US-20080039491-A1 SUBSTITUTED PYRAZOLOPYRIDINES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE DPYD, TYMP, PCK2 KDR 2947/4885KIT 358/4885FLT3 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.